Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 75 versus RENORMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 75 versus RENORMAX.
HYPAQUE-M,75% vs RENORMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast due to high iodine content. It increases the density of vascular structures and tissues, allowing visualization of anatomical structures during imaging procedures.
Selective beta-1 adrenergic receptor antagonist; reduces cardiac output, heart rate, and blood pressure by blocking catecholamine effects on cardiac beta-1 receptors.
1.2-1.5 mL/kg IV as a single dose for CT enhancement; maximum 150 mL per procedure.
5 mg intravenously every 12 hours
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria).
Terminal elimination half-life: 8-10 hours in healthy adults. Prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min). Provides basis for twice-daily dosing in normal renal function.
Renal excretion: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Primarily renal (60-70% unchanged; 10-15% as glucuronide conjugate); biliary/fecal (5-10%); 80-85% total recovered in urine and feces within 72 hours.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent